
François Curtin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4583445/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology, 2002, 31, 140-149.	1.9	1,999
2	Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statistics in Medicine, 2002, 21, 2131-2144.	1.6	192
3	Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Statistics in Medicine, 2002, 21, 2145-2159.	1.6	113
4	Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Statistics in Medicine, 2002, 21, 2161-2173.	1.6	112
5	MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment. Journal of Neuroimmunology, 2016, 291, 29-38.	2.3	70
6	GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study. Clinical Therapeutics, 2012, 34, 2268-2278.	2.5	68
7	Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. MAbs, 2015, 7, 265-275.	5.2	68
8	The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity. PLoS ONE, 2013, 8, e53623.	2.5	64
9	Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. Journal of Affective Disorders, 2004, 78, 201-208.	4.1	54
10	A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 885-893.	3.0	53
11	Relation of BMI to a dual-energy X-ray absorptiometry measure of fatness. British Journal of Nutrition, 1999, 82, 49-55.	2.3	49
12	Psychological distress in fibromyalgia patients: A role for catechol-O-methyl-transferase Val158met polymorphism Health Psychology, 2012, 31, 242-249.	1.6	42
13	Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clinical Pharmacology and Therapeutics, 2021, 109, 1668-1676.	4.7	42
14	A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up. Journal of Neuroimmunology, 2015, 285, 68-70.	2.3	41
15	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Multiple Sclerosis Journal, 2022, 28, 429-440.	3.0	40
16	Impact of SARSâ€CoVâ€2 Infection (COVIDâ€19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clinical Pharmacology and Therapeutics, 2021, 110, 1358-1367.	4.7	36
17	A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an antiâ€HERVâ€Wâ€Env monoclonal antibody. Diabetes, Obesity and Metabolism, 2018, 20, 2075-2084.	4.4	32
18	Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 888-892.	3.0	31

François Curtin

#	Article	IF	CITATIONS
19	Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. EBioMedicine, 2016, 6, 190-198.	6.1	30
20	Prevention of clinical and histological signs of MOC-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF. Journal of Neuroimmunology, 2019, 332, 224-232.	2.3	29
21	Novel therapeutic options for multiple sclerosis. Expert Review of Clinical Pharmacology, 2014, 7, 91-104.	3.1	22
22	Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study. MAbs, 2016, 8, 854-860.	5.2	18
23	Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e144.	6.0	16
24	Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis. Molecular Diagnosis and Therapy, 2015, 19, 255-265.	3.8	16
25	A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis – Rationale and design. Multiple Sclerosis and Related Disorders, 2016, 9, 95-100.	2.0	15
26	The role of adaptive trial designs in drug development. Expert Review of Clinical Pharmacology, 2017, 10, 727-736.	3.1	14
27	Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. Journal of Psychopharmacology, 2002, 16, 271-272.	4.0	13
28	Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review. Drug Safety, 2020, 43, 1287-1296.	3.2	12
29	Metaâ€analysis combining parallel and crossâ€over trials with random effects. Research Synthesis Methods, 2017, 8, 263-274.	8.7	10
30	A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env. Clinical Therapeutics, 2019, 41, 1737-1746.	2.5	10
31	Psychosocial Profile of Swiss Sexual Offenders. Journal of Forensic Sciences, 1998, 43, 755-759.	1.6	10
32	A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1111-1121.	4.4	9
33	Corrections to effect size variances for continuous outcomes of crossover clinical trials. Statistics in Medicine, 2018, 37, 320-323.	1.6	8
34	Metaâ€∎nalysis combining parallel and crossover trials using generalised estimating equation method. Research Synthesis Methods, 2017, 8, 312-320.	8.7	5
35	GABAergic modulation of secondary hyperalgesia: A randomized controlled 4â€way crossover trial with the α2â€subunit preferring GABA positive allosteric modulator, <i>N</i> â€desmethylâ€clobazam in healthy volunteers. European Journal of Pain, 2020, 24, 1094-1106.	2.8	3
36	Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?. Journal of Neurology & Neurophysiology, 2014, 05, .	0.1	1

#	Article	IF	CITATIONS
37	Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients. Frontiers in Genetics, 2021, 12, 816908.	2.3	1